Spazmoblock
Spazmoblock: instructions for use and reviews
- 1. Release form and composition
- 2. Pharmacological properties
- 3. Indications for use
- 4. Contraindications
- 5. Method of application and dosage
- 6. Side effects
- 7. Overdose
- 8. Special instructions
- 9. Application during pregnancy and lactation
- 10. Use in childhood
- 11. In case of impaired renal function
- 12. For violations of liver function
- 13. Drug interactions
- 14. Analogs
- 15. Terms and conditions of storage
- 16. Terms of dispensing from pharmacies
- 17. Reviews
- 18. Price in pharmacies
Latin name: Spasmoblock
ATX code: N02BB52
Active ingredients: Metamizole sodium + Pitofenone + Fenpiverinium bromide (Metamizole natrium + Pitofenone + Fenpiverinium bromide)
Manufacturer: Adipharm, EAD (Adipharm, EAD) (Bulgaria)
Description and photo update: 2019-30-12
Prices in pharmacies: from 112 rubles.
Buy
Spasmoblock is a combined pain reliever (non-narcotic analgesic + antispasmodic).
Release form and composition
Dosage form - tablets: white with a faint yellow tint, flat-cylindrical, round, on one side there is a dividing line (in a cardboard box 2 or 10 blisters containing 10 tablets each, or 1 blister containing 2 tablets, and instructions for use Spasmoblock).
Composition for 1 tablet (500 mg + 5 mg + 0.1 mg):
- active substances: metamizole sodium monohydrate - 527 mg (in terms of metamizole sodium - 500 mg); pitofenone hydrochloride - 5.25 mg (in terms of pitofenone - 5 mg); fenpiverinium bromide - 0.1 mg;
- auxiliary components: microcrystalline cellulose - 25 mg; talc - 6 mg; sodium bicarbonate - 5 mg; magnesium stearate - 4 mg; lactose monohydrate - 5 mg; wheat starch - 38.65 mg; gelatin - 4 mg.
Pharmacological properties
Pharmacodynamics
Spasmoblock is a combined analgesic and antispasmodic drug, the combination of active components of which mutually enhances their therapeutic effect on the body.
Pharmacological efficacy and mechanism of action of Spazmoblock components:
- metamizole sodium: a pyrazolone derivative whose clinical efficacy is associated with inhibition of prostaglandin synthesis. The substance has an antipyretic and analgesic, as well as a weak anti-inflammatory effect;
- pitofenone: myotropic antispasmodic, as part of the drug has a direct effect on the smooth muscles of the internal organs, which contributes to its relaxation;
- fenpiverinium bromide: refers to m-anticholinergics. Thanks to him, the drug has an additional antispasmodic effect on smooth muscles.
Pharmacokinetics
The main pharmacokinetic characteristics of sodium metamizole:
- absorption: absorbed from the gastrointestinal tract quickly and well;
- distribution and metabolism: metamizole sodium is hydrolyzed in the intestinal wall to form an active metabolite. It is not found unchanged in the blood; only after intravenous administration, its insignificant content in the blood plasma is noted. The connection of the active metabolite with blood plasma proteins varies from 50 to 60%. Further, the intensive biotransformation of the substance occurs in the liver with the formation of the main metabolites - 4-methylaminoantipyrine, 4-aminoantipyrine, 4-formylaminoantipyrine and 4-acetylaminoantipyrine, which penetrate into the cerebrospinal fluid. In addition, up to 20 additional metabolites can be identified, including derivatives of glucuronic acid;
- excretion: Metamizole sodium is excreted by the kidneys. Penetrates into breast milk when used in therapeutic doses.
The main pharmacokinetic characteristics of pitofenone:
- absorption: the substance is well absorbed from the gastrointestinal tract. Its maximum concentration in blood plasma is achieved over a period of 30 to 60 minutes;
- distribution: intensively distributed in tissues and organs, does not penetrate through the blood-brain barrier;
- excretion: excreted in the urine quickly enough. Its half-life is 1.8 hours.
The main pharmacokinetic characteristics of fenpiverinium bromide:
- absorption: absorbed from the gastrointestinal tract quickly. Its maximum concentration in blood plasma is reached within 60 minutes;
- excretion: does not penetrate the blood-brain barrier; it is excreted by the kidneys by 32.4–40.4% unchanged, by 2.5–5.3% - with bile.
Indications for use
- pain syndrome with spasms of smooth muscles of internal organs of mild or moderate severity: algomenorrhea, chronic colitis, postcholecystectomy syndrome, hyperkinetic biliary dyskinesia, intestinal / biliary / renal colic, spasm of the bladder and ureter; pathology of the pelvic organs;
- sciatica, neuralgia, myalgia, arthralgia (for short-term treatment);
- pain syndrome after diagnostic procedures and surgical interventions (as an auxiliary therapy).
Contraindications
Absolute:
- severe hepatic and / or renal failure;
- intestinal obstruction;
- oppression of bone marrow hematopoiesis;
- deficiency of glucose-6-phosphate dehydrogenase;
- tachyarrhythmia;
- hyperplasia of the prostate (with clinical symptoms);
- severe angina;
- megacolon;
- angle-closure glaucoma;
- collapse;
- glucose-galactose malabsorption, lactose intolerance, lactase deficiency;
- pregnancy;
- period of breastfeeding;
- children under 8 years old;
- individual intolerance to the components of the drug, including pyrazolone derivatives.
Relative (Spazmoblock tablets are used under medical supervision):
- impaired liver and / or kidney function;
- tendency to arterial hypotension;
- bronchospasm;
- complete or incomplete combination of nasal polyposis and bronchial asthma with intolerance to acetylsalicylic acid and other non-steroidal anti-inflammatory drugs;
- individual intolerance to non-steroidal anti-inflammatory drugs.
Spazmoblock, instructions for use: method and dosage
Spazmoblock tablets are taken orally with water, after meals.
The frequency of application of the drug is from 2 to 3 times a day.
The recommended dosage regimen, depending on the patient's age, is:
- children from 8 to 11 years old: the recommended single dose is ½ pcs., the maximum daily dose is 4 pcs.;
- adolescents from 12 to 14 years old: 1 pc., maximum daily dose - 6 pcs.;
- adolescents over 15 years old and adults: 1–2 pcs. 2-3 times a day. The maximum daily dose is 6 pcs.
The duration of therapy should not exceed 5 days. An increase in the daily dose of the Spasmoblock or the duration of its use is possible only under medical supervision.
Side effects
Possible side reactions of Spasmoblock [more than 10% - very often; (> 1% and 0.1% and 0.01% and <0.1%) - rarely; (<0.01%, including isolated messages) - very rare]:
- digestive system: very rarely - dry mouth, burning sensation in the epigastric region;
- cardiovascular system: rarely - tachycardia, decreased blood pressure;
- hematopoietic system: very rarely (in most cases with prolonged use) - agranulocytosis (can manifest itself as stomatitis, difficulty swallowing, sore throat, chills, unmotivated temperature rise, proctitis, vaginitis phenomena), leukopenia, thrombocytopenia;
- urinary system: rarely (usually with prolonged use or when taken in high doses) - difficulty urinating, urine staining red, interstitial nephritis, proteinuria, anuria, oliguria, renal dysfunction;
- allergic reactions: rarely - urticaria, including localization on the mucous membranes of the nasopharynx and conjunctiva; very rarely - anaphylactic shock, bronchospastic syndrome, Lyell's syndrome (toxic epidermal necrolysis), Stevens-Johnson syndrome (malignant exudative erythema), angioedema;
- others: dizziness is possible; very rarely - paresis of accommodation, decreased sweating; in isolated cases - headache.
Overdose
The main symptoms of an overdose of a Spasmodic block are nausea, convulsions, vomiting, impaired liver and kidney function, decreased blood pressure, pain in the epigastric region, drowsiness, confusion.
In case of accidental intake of high doses of the drug, gastric lavage, intake of absorbents (activated carbon), symptomatic treatment are recommended.
special instructions
Metamizole sodium metabolite can cause urine staining in red, which has no clinical significance and disappears on its own after the end of treatment.
Cancellation of therapy is necessary in the presence of thrombocytopenia and suspected agranulocytosis.
Long-term (more than 7 days) use of the Spasmoblock requires monitoring the functional state of the liver and the picture of peripheral blood.
The drug should not be used to relieve acute abdominal pain until the cause of its occurrence is identified.
Treatment with Spazmoblok against the background of hay fever or bronchial asthma is accompanied by an increased likelihood of allergic reactions.
During the period of therapy, alcohol should not be consumed.
Influence on the ability to drive vehicles and complex mechanisms
Patients during the period of taking Spazmoblock should refuse to drive vehicles and conduct potentially hazardous activities, the implementation of which requires an increased concentration of attention and speed of psychomotor reactions.
Application during pregnancy and lactation
A spasmodic block is not prescribed during pregnancy / lactation.
Pediatric use
In patients under 8 years of age, the Spasmoblock is not used.
With impaired renal function
- use is contraindicated: severe renal failure;
- the appointment requires medical supervision: impaired renal function.
For violations of liver function
- use is contraindicated: severe hepatic failure;
- the appointment requires medical supervision: liver dysfunction.
Drug interactions
Possible interactions of the Spasmoblock with other drugs / substances:
- other non-opioid analgesics: mutual enhancement of their effects is possible;
- allopurinol, oral contraceptives, tricyclic antidepressants: increase toxicity and disrupt the metabolism of metamizole sodium in the liver;
- phenylbutazone, barbiturates and other inducers of microsomal liver enzymes: weaken the effect of sodium metamizole;
- cyclosporine: its concentration in the blood decreases;
- indomethacin, glucocorticosteroids, indirect anticoagulants, oral hypoglycemic drugs: the severity of the action of these drugs may increase as a result of their displacement by metamizole sodium from the connection with plasma proteins;
- tranquilizers, sedatives: enhance the analgesic effect of the Spasmoblock;
- quinidine, amantadine, phenothiazine, butyrophenone derivatives, blockers of H1-histamine receptors: their m-cholinolytic effectiveness is likely to increase;
- ethanol: mutual amplification of effects is possible.
Penicillins, colloidal blood substitutes and X-ray contrast agents should not be used during the period of therapy with drugs that include sodium metamizole.
Analogs
The analogues of Spazmoblok are Trinalgin, Spazmaton, Spazmalin, Spazmalgon, Spazgan, Renalgan, Revalgin, Plenalgin, Maksigan, Bralangin, Spazmo-Apotel, Baralgetas, etc.
Terms and conditions of storage
Store in a place protected from light and moisture at temperatures up to 25 ° C. Keep out of the reach of children.
The shelf life is 3 years.
Terms of dispensing from pharmacies
Available without a prescription.
Reviews about Spazmoblok
According to reviews, Spazmoblock is a safe, effective, fast-acting and affordable drug used in the treatment of pain syndrome.
Among the shortcomings, patients mainly note the presence of a wide list of side effects against the background of the use of Spasmoblock, as well as the large size of the tablets, which makes them inconvenient to swallow.
Price for Spazmoblock in pharmacies
The approximate price for Spazmoblock, tablets (500 mg + 5 mg + 0.1 mg), for 20 pcs. in the package is 134 rubles.
Spazmoblock: prices in online pharmacies
|
Drug name Price Pharmacy |
|
Spazmoblok tablets 20 pcs. 112 RUB Buy |
Maria Kulkes Medical journalist About the author
Education: First Moscow State Medical University named after I. M. Sechenov, specialty "General Medicine".
Information about the drug is generalized, provided for informational purposes only and does not replace the official instructions. Self-medication is hazardous to health!
